ESR1 and breast carcinoma: Considering the significance in this finding, the authors recommended that the AR be considered as one of three prognostic markers to classify breast cancers as triple-positive (ER, HER2, and AR-expressing) or triple-negative (ER, HER2, and AR-negative).